SARS-CoV-2 Nucleocapsid Plasma Antigen for Diagnosis and Monitoring of COVID-19.
Journal
Clinical chemistry
ISSN: 1530-8561
Titre abrégé: Clin Chem
Pays: England
ID NLM: 9421549
Informations de publication
Date de publication:
30 12 2021
30 12 2021
Historique:
received:
30
05
2021
accepted:
10
09
2021
pubmed:
5
10
2021
medline:
3
2
2022
entrez:
4
10
2021
Statut:
ppublish
Résumé
Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid antigen in blood has been described, but the diagnostic and prognostic role of antigenemia is not well understood. This study aimed to determine the frequency, duration, and concentration of nucleocapsid antigen in plasma and its association with coronavirus disease 2019 (COVID-19) severity. We utilized an ultrasensitive electrochemiluminescence immunoassay targeting SARS-CoV-2 nucleocapsid antigen to evaluate 777 plasma samples from 104 individuals with COVID-19. We compared plasma antigen to respiratory nucleic acid amplification testing (NAAT) in 74 individuals with COVID-19 from samples collected ±1 day of diagnostic respiratory NAAT and in 52 SARS-CoV-2-negative individuals. We used Kruskal-Wallis tests, multivariable logistic regression, and mixed-effects modeling to evaluate whether plasma antigen concentration was associated with disease severity. Plasma antigen had 91.9% (95% CI 83.2%-97.0%) clinical sensitivity and 94.2% (84.1%-98.8%) clinical specificity. Antigen-negative plasma samples belonged to patients with later respiratory cycle thresholds (Ct) when compared with antigen-positive plasma samples. Median plasma antigen concentration (log10 fg/mL) was 5.4 (interquartile range 3.9-6.0) in outpatients, 6.0 (5.4-6.5) in inpatients, and 6.6 (6.1-7.2) in intensive care unit (ICU) patients. In models adjusted for age, sex, diabetes, and hypertension, plasma antigen concentration at diagnosis was associated with ICU admission [odds ratio 2.8 (95% CI 1.2-6.2), P=.01] but not with non-ICU hospitalization. Rate of antigen decrease was not associated with disease severity. SARS-CoV-2 plasma nucleocapsid antigen exhibited comparable diagnostic performance to upper respiratory NAAT, especially among those with late respiratory Ct. In addition to currently available tools, antigenemia may facilitate patient triage to optimize intensive care utilization.
Sections du résumé
BACKGROUND
Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid antigen in blood has been described, but the diagnostic and prognostic role of antigenemia is not well understood. This study aimed to determine the frequency, duration, and concentration of nucleocapsid antigen in plasma and its association with coronavirus disease 2019 (COVID-19) severity.
METHODS
We utilized an ultrasensitive electrochemiluminescence immunoassay targeting SARS-CoV-2 nucleocapsid antigen to evaluate 777 plasma samples from 104 individuals with COVID-19. We compared plasma antigen to respiratory nucleic acid amplification testing (NAAT) in 74 individuals with COVID-19 from samples collected ±1 day of diagnostic respiratory NAAT and in 52 SARS-CoV-2-negative individuals. We used Kruskal-Wallis tests, multivariable logistic regression, and mixed-effects modeling to evaluate whether plasma antigen concentration was associated with disease severity.
RESULTS
Plasma antigen had 91.9% (95% CI 83.2%-97.0%) clinical sensitivity and 94.2% (84.1%-98.8%) clinical specificity. Antigen-negative plasma samples belonged to patients with later respiratory cycle thresholds (Ct) when compared with antigen-positive plasma samples. Median plasma antigen concentration (log10 fg/mL) was 5.4 (interquartile range 3.9-6.0) in outpatients, 6.0 (5.4-6.5) in inpatients, and 6.6 (6.1-7.2) in intensive care unit (ICU) patients. In models adjusted for age, sex, diabetes, and hypertension, plasma antigen concentration at diagnosis was associated with ICU admission [odds ratio 2.8 (95% CI 1.2-6.2), P=.01] but not with non-ICU hospitalization. Rate of antigen decrease was not associated with disease severity.
CONCLUSIONS
SARS-CoV-2 plasma nucleocapsid antigen exhibited comparable diagnostic performance to upper respiratory NAAT, especially among those with late respiratory Ct. In addition to currently available tools, antigenemia may facilitate patient triage to optimize intensive care utilization.
Identifiants
pubmed: 34605900
pii: 6380945
doi: 10.1093/clinchem/hvab216
pmc: PMC8522398
doi:
Substances chimiques
Antigens, Viral
0
Coronavirus Nucleocapsid Proteins
0
Phosphoproteins
0
nucleocapsid phosphoprotein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
204-213Subventions
Organisme : NIH HHS
ID : UL1 TR001085
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR003142
Pays : United States
Organisme : NIH HHS
ID : 1U54CA260517
Pays : United States
Informations de copyright
© American Association for Clinical Chemistry 2021.
Références
J Am Coll Cardiol. 2020 Aug 4;76(5):533-546
pubmed: 32517963
Clin Infect Dis. 2006 Jul 1;43(1):e1-5
pubmed: 16758408
Clin Infect Dis. 2021 Aug 2;73(3):e799-e802
pubmed: 32888003
Am J Hematol. 2020 Jul;95(7):834-847
pubmed: 32282949
Sci Immunol. 2020 Dec 7;5(54):
pubmed: 33288645
Nat Commun. 2020 Oct 30;11(1):5493
pubmed: 33127906
J Clin Virol. 2020 Aug;129:104427
pubmed: 32535398
Clin Infect Dis. 2021 Dec 16;73(12):2326-2328
pubmed: 33830203
Sci China Life Sci. 2021 Jul;64(7):1193-1196
pubmed: 33259038
Emerg Infect Dis. 2004 Nov;10(11):1947-9
pubmed: 15550204
Clin Microbiol Infect. 2020 Dec 8;:
pubmed: 33307227
Clin Infect Dis. 2021 Nov 2;73(9):e2890-e2897
pubmed: 32803231
Clin Chem. 2020 Dec 1;66(12):1562-1572
pubmed: 32897389
Acad Emerg Med. 2021 Mar;28(3):306-313
pubmed: 33481307
Clin Infect Dis. 2021 Aug 2;73(3):e803-e804
pubmed: 32941602
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Cochrane Database Syst Rev. 2021 Mar 24;3:CD013705
pubmed: 33760236
JAMA. 2020 May 19;323(19):1967-1969
pubmed: 32250394
Clin Infect Dis. 2020 Dec 17;71(10):2663-2666
pubmed: 32442256
BMJ. 2020 Apr 7;369:m1328
pubmed: 32265220
Lancet Microbe. 2021 Jan;2(1):e13-e22
pubmed: 33521734
Nat Rev Immunol. 2020 Jul;20(7):389-391
pubmed: 32439870
Clin Infect Dis. 2021 May 4;72(9):e291-e295
pubmed: 32965474
Clin Infect Dis. 2021 Dec 6;73(11):e4197-e4205
pubmed: 32603425
Cochrane Database Syst Rev. 2020 Nov 19;11:CD013787
pubmed: 33211319
Eur J Clin Microbiol Infect Dis. 2020 Jun;39(6):1059-1061
pubmed: 32342252
Epidemiology. 1990 Jan;1(1):43-6
pubmed: 2081237
EClinicalMedicine. 2020 Aug;25:100449
pubmed: 32838231
Clin Infect Dis. 2021 May 18;72(10):e685-e686
pubmed: 32785682